[Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
D002994:Clofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D005233:Fatty Alcohols / Q000009:adverse effects / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009135:Muscular Diseases / Q000139:chemically induced; D010146:Pain
D005233:Fatty Alcohols; D000960:Hypolipidemic Agents; C004568:tiadenol; D002994:Clofibrate
Tollerabilità ed effetti secondari del bis-(idrossi-2-etiltio)-1,10-decano (BS 530) rispetto al clofibrato nella terapia delle iperlipemie.